Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 12;12:630429. doi: 10.3389/fimmu.2021.630429

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Gagelmann, Wolschke, Klyuchnikov, Christopeit, Ayuk and Kröger.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The impact of TKI therapy on secondary end points of overall survival and non-relapse mortality. Significantly improved outcome for TKI therapy was also seen in overall survival (A), which was assessed in 6 studies. The overall pooled RR was 0.48 (95% CI, 0.36–0.64; P < 0.001) in favor of the TKI therapy with no relevant heterogeneity (I² = 0%). Subgroup analyses showed no significant difference in outcome between midostaurin and sorafenib (P = 0.30). Non-relapse mortality (B) was assessed in 5 studies, which evaluated the efficacy of sorafenib. No significant difference between sorafenib and the control was seen, showing an overall pooled RR of 0.87 (95% CI, 0.51–1.47; P = 0.60) with no relevant heterogeneity (I² = 0%).